Sameer Ralhan
Known title: SVP, Chief Financial OfficerCIK: 0001778813
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Chemours Q2 Earnings Call and UBS Price Target Cut. Chemours released its Q2 2026 earnings call transcript, providing details on its financial performance. UBS kept a neutral stance but lowered its price target to $16, reflecting a more cautious view of the company's outlook. The new target sits below the current average analyst target of $18.22 and near the support level of $15.07, indicating a potential short‑term pressure on the stock.
Transaction History
| VLTO | ▼ Sell | Tax Withholding | 3,305 | $301K | 7/15/2026 | View on chart |
| VLTO | ▲ Buy | Grant | 7,313 | $0 | 3/1/2026 | View on chart |
| VLTO | ▼ Sell | Tax Withholding | 3,361 | $332K | 11/14/2025 | View on chart |
| VLTO | ▲ Buy | Grant | 6,767 | $0 | 3/1/2025 | View on chart |
| VLTO | ▼ Sell | Tax Withholding | 3,833 | $394K | 11/18/2024 | View on chart |
| VLTO | ▲ Buy | Grant | 7,497 | $0 | 2/24/2024 | View on chart |
| VLTO | ▲ Buy | Grant | 27,060 | $0 | 11/15/2023 | View on chart |
| VLTO | ▲ Buy | Grant | 15,556 | — | 9/30/2023 | View on chart |
| CC | ▲ Buy | Grant | 12,378 | $0 | 3/1/2023 | View on chart |
| CC | ▼ Sell | Tax Withholding | 1,842 | $64K | 3/1/2023 | View on chart |
| CC | ▼ Sell | Tax Withholding | 42,218 | $1.5M | 2/10/2023 | View on chart |
| CC | ▲ Buy | Grant | 98,360 | $0 | 2/10/2023 | View on chart |
| CC | ▲ Buy | Option Exercise | 20,175 | $109K | 5/9/2022 | View on chart |
| CC | ▼ Sell | Open Market | 20,175 | $807K | 5/9/2022 | View on chart |
| CC | ▲ Buy | Option Exercise | 35,188 | $190K | 5/6/2022 | View on chart |
| CC | ▼ Sell | Open Market | 35,188 | $1.4M | 5/6/2022 | View on chart |
| CC | ▲ Buy | Grant | 6,254 | $0 | 3/1/2022 | View on chart |
| CC | ▼ Sell | Tax Withholding | 550 | $14K | 3/1/2022 | View on chart |
| CC | ▲ Buy | Grant | 11,864 | $0 | 2/11/2022 | View on chart |
| CC | ▼ Sell | Tax Withholding | 3,975 | $119K | 2/11/2022 | View on chart |
| CC | ▲ Buy | Option Exercise | 17,482 | $323K | 12/2/2021 | View on chart |
| CC | ▼ Sell | Open Market | 17,482 | $522K | 12/2/2021 | View on chart |
| CC | ▲ Buy | Option Exercise | 1,890 | $35K | 8/30/2021 | View on chart |
| CC | ▼ Sell | Open Market | 1,890 | $66K | 8/30/2021 | View on chart |
| CC | ▲ Buy | Option Exercise | 15,085 | $278K | 8/27/2021 | View on chart |
| CC | ▼ Sell | Open Market | 15,085 | $528K | 8/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Veralto Sets Date for Q3 2026 Earnings Call
Veralto has announced the schedule for its third-quarter 2026 earnings call, providing investors with a specific date to review upcoming financial results. This announcement is a standard corporate disclosure that helps the market prepare for the next major update on the company's performance. The stock is currently trading near its 52-week high, reflecting strong recent momentum ahead of this scheduled event.
Veralto Sets Date for Q3 2026 Earnings Call. Veralto has announced the schedule for its third-quarter 2026 earnings call, providing investors with a specific date to review upcoming financial results. This announcement is a standard corporate disclosure that helps the market prepare for the next major update on the company's performance. The stock is currently trading near its 52-week high, reflecting strong recent momentum ahead of this scheduled event.